Literature DB >> 10992535

Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice.

S Lim1, A Jatakanon, D Gordon, C Macdonald, K F Chung, P J Barnes.   

Abstract

BACKGROUND: Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has anti-inflammatory or immunomodulatory effects. A study was undertaken to determine whether theophylline added to low dose inhaled steroids would be as efficacious as high dose inhaled steroids in asthma.
METHODS: In a study in general practice of 155 recruited asthmatic patients with continuing symptomatic asthma while on 400 microgram beclomethasone dipropionate (BDP) daily and inhaled beta(2) agonist as required, the effect of (1) continuing low dose inhaled steroids alone (LDS, 200 microgram BDP twice daily), (2) low dose inhaled steroids plus low dose theophylline (LDT, 400 mg daily), or (3) high dose inhaled steroids (HDS, 500 microgram BDP) over a six month period was examined.
RESULTS: One hundred and thirty patients completed the study. Between group comparison using analysis of variance showed no overall differences in peak flow measurements, diurnal variation, and symptom scores. Changes in evening peak flows approached significance at the 5% level (p=0.077). The mean improvement in evening peak flow in the LDT compared with the LDS group was 20.6 l/min (95% confidence interval (CI) -2.5 to 38.8). In the LDT group there was an increase in evening peak flows at the end of the study compared with entry values (22.5 l/min), while in the LDS and HDS groups evening peak flows increased by 1.9 and 8.3 l/min, respectively. There was no significant difference in exacerbations or in side effects.
CONCLUSION: There were no overall significant differences between the low dose steroid, low dose steroid with theophylline, and the high dose steroid groups. The greatest within-group improvement in evening peak flows was found after theophylline. A larger study may be necessary to show significant effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992535      PMCID: PMC1745610          DOI: 10.1136/thorax.55.10.837

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study.

Authors:  J P Finnerty; C Lee; S Wilson; J Madden; R Djukanovic; S T Holgate
Journal:  Eur Respir J       Date:  1996-08       Impact factor: 16.671

Review 2.  Theophylline in chronic asthma--evidence for disease-modifying properties.

Authors:  K F Chung
Journal:  Clin Exp Allergy       Date:  1996-03       Impact factor: 5.018

3.  Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma.

Authors:  D Ukena; U Harnest; R Sakalauskas; P Magyar; N Vetter; H Steffen; S Leichtl; F Rathgeb; A Keller; V W Steinijans
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

4.  A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

Authors:  D J Evans; D A Taylor; O Zetterstrom; K F Chung; B J O'Connor; P J Barnes
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

5.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

Authors:  R A Pauwels; C G Löfdahl; D S Postma; A E Tattersfield; P O'Byrne; P J Barnes; A Ullman
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

6.  Anti-inflammatory effects of theophylline: modulation of cytokine production.

Authors:  J J Mascali; P Cvietusa; J Negri; L Borish
Journal:  Ann Allergy Asthma Immunol       Date:  1996-07       Impact factor: 6.347

7.  Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy.

Authors:  J Kidney; M Dominguez; P M Taylor; M Rose; K F Chung; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1995-06       Impact factor: 21.405

8.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group.

Authors:  A P Greening; P W Ind; M Northfield; G Shaw
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

9.  Theophylline inhibits the release of eosinophil survival cytokines--is Raf-1 the protein kinase A target?

Authors:  J K Shute; H Tenor; M K Church; S T Holgate
Journal:  Clin Exp Allergy       Date:  1998-08       Impact factor: 5.018

10.  Comparison of patients' compliance with prescribed oral and inhaled asthma medications.

Authors:  J S Kelloway; R A Wyatt; S A Adlis
Journal:  Arch Intern Med       Date:  1994-06-27
View more
  18 in total

Review 1.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 2.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

3.  Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations.

Authors:  Ritesh Agarwal; Sahajal Dhooria; Ashutosh Nath Aggarwal; Venkata N Maturu; Inderpaul S Sehgal; Valliappan Muthu; Kuruswamy T Prasad; Lakshmikant B Yenge; Navneet Singh; Digambar Behera; Surinder K Jindal; Dheeraj Gupta; Thanagakunam Balamugesh; Ashish Bhalla; Dhruva Chaudhry; Sunil K Chhabra; Ramesh Chokhani; Vishal Chopra; Devendra S Dadhwal; George D'Souza; Mandeep Garg; Shailendra N Gaur; Bharat Gopal; Aloke G Ghoshal; Randeep Guleria; Krishna B Gupta; Indranil Haldar; Sanjay Jain; Nirmal K Jain; Vikram K Jain; Ashok K Janmeja; Surya Kant; Surender Kashyap; Gopi C Khilnani; Jai Kishan; Raj Kumar; Parvaiz A Koul; Ashok Mahashur; Amit K Mandal; Samir Malhotra; Sabir Mohammed; Prasanta R Mohapatra; Dharmesh Patel; Rajendra Prasad; Pallab Ray; Jai K Samaria; Potsangbam Sarat Singh; Honey Sawhney; Nusrat Shafiq; Navneet Sharma; Updesh Pal S Sidhu; Rupak Singla; Jagdish C Suri; Deepak Talwar; Subhash Varma
Journal:  Lung India       Date:  2015-04

Review 4.  Asthma in adults.

Authors:  Rodolfo J Dennis; Ivan Solarte; Gustavo Rodrigo
Journal:  BMJ Clin Evid       Date:  2011-07-13

Review 5.  Asthma in adults.

Authors:  Rodolfo J Dennis; Ivan Solarte; Gustavo Rodrigo
Journal:  BMJ Clin Evid       Date:  2010-01-21

6.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.

Authors:  Yasuo To; Kazuhiro Ito; Yasuo Kizawa; Marco Failla; Misako Ito; Tadashi Kusama; W Mark Elliott; James C Hogg; Ian M Adcock; Peter J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

Review 7.  Single-inhaler combination therapy for asthma: a review of cost effectiveness.

Authors:  Manabu Akazawa; David A Stempel
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

Authors:  M A Giembycz
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

9.  A meta-analysis on the efficacy of oral theophylline in patients with stable COPD.

Authors:  Néstor A Molfino; Peter Zhang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Severe asthma in children.

Authors:  Theresa W Guilbert; Leonard B Bacharier; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.